3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
5
Phase 3
3
Phase 1/2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Prostatic Neoplasms
2
Glioblastoma
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Neoplasm Metastasis
1
Gliosarcoma
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Trastuzumab
62
Paclitaxel
57
Cyclophosphamide
44
pembrolizumab
34
Fulvestrant
34
Capecitabine
29
Carboplatin
26
Docetaxel
23
Letrozole
22
Doxorubicin
19
palbociclib
16
abemaciclib
16
pertuzumab
15
durvalumab
14
Filgrastim
13
Everolimus
13
ribociclib
12
Lapatinib
12
Gemcitabine
12
exemestane
11
eribulin
11
Vinorelbine
11
Albumin-Bound Paclitaxel
11
Bevacizumab
10
trastuzumab deruxtecan
9
neratinib
9
fludarabine
9
Taxes
9
Radiotherapy
9
Peripheral Blood Stem Cell Transplantation
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Breast Neoplasms
×
ipatasertib
×
Clear all
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled
NCT03280563
2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2
Completed
144 enrolled
25 charts